片仔癀(600436.SH):PZH2108片Ⅱa期临床试验完成首例受试者入组

Core Viewpoint - The company Pianzaihuang (600436.SH) has announced the initiation of a Phase IIa clinical trial for its innovative chemical drug PZH2108, which aims to evaluate safety, tolerability, preliminary clinical efficacy, pharmacokinetics, and pharmacodynamics in cancer patients [1] Group 1 - The Phase IIa clinical trial is a multicenter, randomized, double-blind, placebo-controlled study [1] - The first subject has been enrolled in the trial, marking a significant milestone for the company's research and development efforts [1]